U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

OVARIAN CANCER, EPITHELIAL, SOMATIC

MedGen UID:
358303
•Concept ID:
C1868358
•
Finding
OMIM®: 171834

Professional guidelines

PubMed

PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
Luo L, Keyomarsi K
Expert Opin Investig Drugs 2022 Jun;31(6):607-631. Epub 2022 May 3 doi: 10.1080/13543784.2022.2067527. PMID: 35435784Free PMC Article
Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment.
Kurnit KC, Fleming GF, Lengyel E
Obstet Gynecol 2021 Jan 1;137(1):108-121. doi: 10.1097/AOG.0000000000004173. PMID: 33278287Free PMC Article
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC
J Clin Oncol 2020 Oct 20;38(30):3468-3493. Epub 2020 Aug 13 doi: 10.1200/JCO.20.01924. PMID: 32790492Free PMC Article

Recent clinical studies

Etiology

Single-cell transcriptomic analysis of endometriosis.
Fonseca MAS, Haro M, Wright KN, Lin X, Abbasi F, Sun J, Hernandez L, Orr NL, Hong J, Choi-Kuaea Y, Maluf HM, Balzer BL, Fishburn A, Hickey R, Cass I, Goodridge HS, Truong M, Wang Y, Pisarska MD, Dinh HQ, El-Naggar A, Huntsman DG, Anglesio MS, Goodman MT, Medeiros F, Siedhoff M, Lawrenson K
Nat Genet 2023 Feb;55(2):255-267. Epub 2023 Jan 9 doi: 10.1038/s41588-022-01254-1. PMID: 36624343
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM
J Clin Oncol 2020 Apr 10;38(11):1222-1245. Epub 2020 Jan 27 doi: 10.1200/JCO.19.02960. PMID: 31986064Free PMC Article
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM
Cancer Discov 2019 Feb;9(2):210-219. Epub 2018 Nov 13 doi: 10.1158/2159-8290.CD-18-0715. PMID: 30425037
Molecular diagnosis in type I epithelial ovarian cancer.
Sadłecki P, Walentowicz-Sadłecka M, Grabiec M
Ginekol Pol 2017;88(12):692-697. doi: 10.5603/GP.a2017.0123. PMID: 29303228
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA
Lancet Oncol 2017 Jan;18(1):75-87. Epub 2016 Nov 29 doi: 10.1016/S1470-2045(16)30559-9. PMID: 27908594

Diagnosis

Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer.
Wang Y, Xie H, Chang X, Hu W, Li M, Li Y, Liu H, Cheng H, Wang S, Zhou L, Shen D, Dou S, Ma R, Mao Y, Zhu H, Zhang X, Zheng Y, Ye X, Wen L, Kee K, Cui H, Tang F
Cancer Res 2022 Nov 2;82(21):3903-3916. doi: 10.1158/0008-5472.CAN-21-3819. PMID: 35969151Free PMC Article
Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer.
Paffenholz SV, Salvagno C, Ho YJ, Limjoco M, Baslan T, Tian S, Kulick A, de Stanchina E, Wilkinson JE, Barriga FM, Zamarin D, Cubillos-Ruiz JR, Leibold J, Lowe SW
Proc Natl Acad Sci U S A 2022 Feb 1;119(5) doi: 10.1073/pnas.2117754119. PMID: 35082152Free PMC Article
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
Poveda A, Lheureux S, Colombo N, Cibula D, Lindemann K, Weberpals J, Bjurberg M, Oaknin A, Sikorska M, González-Martín A, Madry R, Pérez MJR, Ledermann J, Davidson R, Blakeley C, Bennett J, Barnicle A, Škof E
Gynecol Oncol 2022 Mar;164(3):498-504. Epub 2022 Jan 19 doi: 10.1016/j.ygyno.2021.12.025. PMID: 35063276
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC
J Clin Oncol 2020 Oct 20;38(30):3468-3493. Epub 2020 Aug 13 doi: 10.1200/JCO.20.01924. PMID: 32790492Free PMC Article
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM
J Clin Oncol 2020 Apr 10;38(11):1222-1245. Epub 2020 Jan 27 doi: 10.1200/JCO.19.02960. PMID: 31986064Free PMC Article

Therapy

PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
Luo L, Keyomarsi K
Expert Opin Investig Drugs 2022 Jun;31(6):607-631. Epub 2022 May 3 doi: 10.1080/13543784.2022.2067527. PMID: 35435784Free PMC Article
Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment.
Kurnit KC, Fleming GF, Lengyel E
Obstet Gynecol 2021 Jan 1;137(1):108-121. doi: 10.1097/AOG.0000000000004173. PMID: 33278287Free PMC Article
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC
J Clin Oncol 2020 Oct 20;38(30):3468-3493. Epub 2020 Aug 13 doi: 10.1200/JCO.20.01924. PMID: 32790492Free PMC Article
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM
J Clin Oncol 2020 Apr 10;38(11):1222-1245. Epub 2020 Jan 27 doi: 10.1200/JCO.19.02960. PMID: 31986064Free PMC Article
Homologous recombination deficiency and ovarian cancer.
Ledermann JA, Drew Y, Kristeleit RS
Eur J Cancer 2016 Jun;60:49-58. Epub 2016 Apr 9 doi: 10.1016/j.ejca.2016.03.005. PMID: 27065456

Prognosis

PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
Luo L, Keyomarsi K
Expert Opin Investig Drugs 2022 Jun;31(6):607-631. Epub 2022 May 3 doi: 10.1080/13543784.2022.2067527. PMID: 35435784Free PMC Article
Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer.
Paffenholz SV, Salvagno C, Ho YJ, Limjoco M, Baslan T, Tian S, Kulick A, de Stanchina E, Wilkinson JE, Barriga FM, Zamarin D, Cubillos-Ruiz JR, Leibold J, Lowe SW
Proc Natl Acad Sci U S A 2022 Feb 1;119(5) doi: 10.1073/pnas.2117754119. PMID: 35082152Free PMC Article
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM
Cancer Discov 2019 Feb;9(2):210-219. Epub 2018 Nov 13 doi: 10.1158/2159-8290.CD-18-0715. PMID: 30425037
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA
Lancet Oncol 2017 Jan;18(1):75-87. Epub 2016 Nov 29 doi: 10.1016/S1470-2045(16)30559-9. PMID: 27908594
Homologous recombination deficiency and ovarian cancer.
Ledermann JA, Drew Y, Kristeleit RS
Eur J Cancer 2016 Jun;60:49-58. Epub 2016 Apr 9 doi: 10.1016/j.ejca.2016.03.005. PMID: 27065456

Clinical prediction guides

PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
Luo L, Keyomarsi K
Expert Opin Investig Drugs 2022 Jun;31(6):607-631. Epub 2022 May 3 doi: 10.1080/13543784.2022.2067527. PMID: 35435784Free PMC Article
Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer.
Paffenholz SV, Salvagno C, Ho YJ, Limjoco M, Baslan T, Tian S, Kulick A, de Stanchina E, Wilkinson JE, Barriga FM, Zamarin D, Cubillos-Ruiz JR, Leibold J, Lowe SW
Proc Natl Acad Sci U S A 2022 Feb 1;119(5) doi: 10.1073/pnas.2117754119. PMID: 35082152Free PMC Article
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM
J Clin Oncol 2020 Apr 10;38(11):1222-1245. Epub 2020 Jan 27 doi: 10.1200/JCO.19.02960. PMID: 31986064Free PMC Article
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA
Lancet Oncol 2017 Jan;18(1):75-87. Epub 2016 Nov 29 doi: 10.1016/S1470-2045(16)30559-9. PMID: 27908594
Homologous recombination deficiency and ovarian cancer.
Ledermann JA, Drew Y, Kristeleit RS
Eur J Cancer 2016 Jun;60:49-58. Epub 2016 Apr 9 doi: 10.1016/j.ejca.2016.03.005. PMID: 27065456

Recent systematic reviews

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC
J Clin Oncol 2020 Oct 20;38(30):3468-3493. Epub 2020 Aug 13 doi: 10.1200/JCO.20.01924. PMID: 32790492Free PMC Article
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM
J Clin Oncol 2020 Apr 10;38(11):1222-1245. Epub 2020 Jan 27 doi: 10.1200/JCO.19.02960. PMID: 31986064Free PMC Article
The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis.
Staropoli N, Ciliberto D, Del Giudice T, Iuliano E, Cucè M, Grillone F, Salvino A, Barbieri V, Russo A, Tassone P, Tagliaferri P
Crit Rev Oncol Hematol 2018 Nov;131:83-89. Epub 2018 Sep 3 doi: 10.1016/j.critrevonc.2018.08.011. PMID: 30293710
Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature.
Ciccone MA, Maoz A, Casabar JK, Machida H, Mabuchi S, Matsuo K
Expert Opin Investig Drugs 2016 Jul;25(7):781-96. Epub 2016 May 13 doi: 10.1080/13543784.2016.1181748. PMID: 27101098Free PMC Article
Somatic mutations in breast and serous ovarian cancer young patients: a systematic review and meta-analysis.
Encinas G, Maistro S, Pasini FS, Katayama ML, Brentani MM, Bock GH, Folgueira MA
Rev Assoc Med Bras (1992) 2015 Sep-Oct;61(5):474-83. doi: 10.1590/1806-9282.61.05.474. PMID: 26603012

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...